歌礼制药：ASC30在美国Ib期研究中展现出良好且具差异化的药代动力学特征

Core Insights - The core point of the article is that Gilead Sciences-B (01672.HK) announced positive results for its ASC30 oral tablet in a Phase Ib multi-dose escalation study in the U.S., demonstrating favorable pharmacokinetic characteristics compared to orforglipron [1] Group 1: Drug Performance - ASC30 shows a drug exposure level approximately 2.3 to 3.3 times higher than orforglipron, indicating a significant advantage in pharmacokinetics [1] - The higher drug exposure and good tolerability of ASC30 suggest it may be more effective than orforglipron [1] Group 2: Future Research - Gilead plans to conduct a Phase IIa study of ASC30 in overweight or obese subjects, with top-line data expected in the fourth quarter of 2025 [1]